Login to Your Account



A Blockbuster in the Making?

Ahead of PDUFA, Ipilimumab Impresses in Melanoma Again

By Jennifer Boggs


Wednesday, March 23, 2011
Ahead of this week's PDUFA date for ipilimumab in second-line metastatic melanoma, the drug hit its endpoint in the first-line setting, as Bristol-Myers Squibb Co.'s 2009 buyout of Medarex Inc. for $2.4 billion just keeps looking better and better.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription